Management of oligometastatic non-small cell lung cancer patients: Current controversies and future directions

Felipe Couñago, Javier Luna, Luis Leonardo Guerrero, Blanca Vaquero, María Cecilia Guillén-Sacoto, Teresa González-Merino, Begoña Taboada, Verónica Díaz, Belén Rubio-Viqueira, Ana Aurora Díaz-Gavela, Francisco José Marcos, Elia del Cerro

Abstract

Oligometastatic non-small cell lung cancer (NSCLC) describes an intermediate stage of NSCLC between localized and widely-disseminated disease. This stage of NSCLC is characterized by a limited number of metastases and a more indolent tumor biology. Currently, the management of oligometastatic NSCLC involves radical treatment (radiotherapy or surgery) that targets the metastatic lesions and the primary tumor to achieve disease control. This approach offers the potential to achieve prolonged survival in patients who, in the past, would have only received palliative measures. The optimal therapeutic strategies for the...
different scenarios of oligometastatic disease (intracranial vs extracranial disease, synchronous vs metachronous) remain undefined. Given the lack of head-to-head studies comparing radiotherapy to surgery in these patients, the decision to apply surgery or radiotherapy (with or without systemic treatment) must be based on prognostic factors that allow us to classify patients. This classification will allow us to select the most appropriate therapeutic strategy on an individualized basis. In the future, the molecular or microRNA profiles will likely improve the treatment selection process. The objective of the present article is to review the most relevant scientific evidence on the management of patients with oligometastatic NSCLC, focusing on the role of radiotherapy and surgery. We also discuss areas of controversy and future directions.

Key words: Non-small cell lung cancer; Metastasectomy; Oligometastases; Stereotactic ablative radiotherapy; Stereotactic body radiation therapy; Radiosurgery

©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: In recent years, numerous studies, including two randomized phase II trials, have demonstrated that local treatment, either radiotherapy or surgery, of the primary tumor and metastases improves progression-free survival and overall survival in patients who present with oligometastatic non-small cell lung cancer at diagnosis and in those who respond to the initial systemic therapy. As we await the results of ongoing randomized phase III trials, the main international clinical guidelines recommend a multimodal strategy to manage this subgroup of oligometastatic patients. Current guidelines recommend systemic therapy combined with local treatment of the metastases and, if applicable, the primary tumor.

Citation: Couñago F, Luna J, Guerrero LL, Vaquero B, Guillén-Sacoto MC, González-Merino T, Taboada B, Díaz V, Rubio-Viqueira B, Díaz-Gavela AA, Marcos FJ, del Cerro E. Management of oligometastatic non-small cell lung cancer patients: Current controversies and future directions. World J Clin Oncol 2019; 10(10): 318-339
URL: https://www.wjgnet.com/2218-4333/full/v10/i10/318.htm
DOI: https://dx.doi.org/10.5306/wjco.v10.i10.318

INTRODUCTION

Lung cancer is the second most common cancer in both men and women and the leading cause of cancer-related death worldwide. Approximately 80% of newly-diagnosed lung cancers in Europe are non-small cell lung cancer (NSCLC), and 60%-70% of these patients have advanced disease at diagnosis[1]. Traditionally, these patients have been managed exclusively with chemotherapy and palliative treatments aimed at relieving symptoms and improving quality of life. Previously, patients with advanced NSCLC were not considered candidates for curative-intent treatment due to their poor prognosis, with a median survival of 8-11 mo and a 5-year overall survival (OS) rate of only 4%-6%. Today, however, the situation has changed significantly. In recent years, advances in diagnostic imaging techniques, including $^{18}$F-FDG-positron-emission tomography (PET)/computed tomography (CT) and brain magnetic resonance imaging (MRI), have substantially increased the tumor detection rate. These advances, together with the emergence of targeted therapies such as anti-epidermal growth factor receptor (EGFR)/anaplastic lymphoma kinase (ALK), have increased survival in patients with metastatic disease, leading to a growing number of patients characterized by a limited number of metastases at only a few sites. This newly-defined patient subgroup represents an intermediate stage of NSCLC between locally-advanced and widely-disseminated disease. Patients with oligometastatic disease have a better long-term prognosis than those with more advanced NSCLC and may benefit from systemic therapy combined with local treatment (mainly radiotherapy and/or surgery) directed at the metastatic lesions[2].

The 8th edition of the Tumor, Node, Metastasis published by the International Association for the Study of Lung Cancer includes, for the first time, oligometastatic disease. These patients are divided into three distinct categories according to their...
Surgery has traditionally been the main treatment option in oligometastatic patients, with a focus on the role of surgery and radiotherapy. We also discuss current controversies and future directions.

DEFINITION OF THE OLIGOMETASTATIC STATE

The oligometastatic state was first described by Hellman and Weichselbaum[4] in an editorial published in 1995, in which the authors proposed their “step-wise” and “seed and soil” hypotheses. Oligometastasis refers to a clinical stage in which patients present a limited number of metastases to a few sites (a single organ or a few organs). These lesions may be more indolent than those typically observed in patients with multiple metastases, and thus these oligometastatic patients have a better prognosis. The incidence of oligometastatic NSCLC is estimated to range from 20%-50%[5] of patients with NSCLC, depending on the specific definition used to define oligometastatic disease (i.e., number of metastases: Three vs five and time of presentation: Synchronous vs metachronous). The most common metastatic site in NSCLC is the brain (60%), followed by multorgan metastases to the contralateral lung, lymph nodes, liver (23%), and adrenal glands (10%)[6].

Data from observational studies suggest that the recurrence pattern in up to 60% of patients diagnosed with oligometastatic NSCLC treated with systemic therapy is mainly local, involving the same sites affected at the time of diagnosis[7]. This pattern of progression supports the application of local treatment to target the individual metastases and the primary tumor in order to improve local control and progression-free survival (PFS). Conceivably, an increase in PFS could improve OS by preventing the uncontrolled growth of the oligometastatic lesions, thus reducing or preventing the progressive dysfunction of the involved organ(s). In recent years, numerous studies, mostly retrospective, have evaluated the treatment of oligometastatic NSCLC. Most of those studies found that administering aggressive local treatment to all of the metastatic lesions improved both PFS and OS.

Oligometastatic disease can be subclassified according to the initial diagnosis and the systemic therapy. The term synchronous or de novo oligometastases refers to the presence at diagnosis of a limited number of metastases. By contrast, oligo-recurrence refers to the development of new, metachronous metastases after definitive treatment of the locoregional thoracic disease[8]. Two other terms, oligoprogression and oligo-resistance, are used to describe patients with disseminated disease at diagnosis that partially respond to systemic treatment (disease stabilization), except for the development of a limited number of metastases that progress (oligoprogression) or persist (oligo-resistance) after systemic chemotherapy. Oligoprogression and oligo-resistance are common in patients treated with targeted therapies (anti-EGFR/anti-ALK) due to acquired resistance after treatment with tyrosine kinase inhibitors (TKI).

To identify accurately oligometastatic patients, the use of modern imaging techniques, such as PET and brain MRI, is essential to detect the presence of occult metastases that are not visible with conventional imaging techniques. MRI is superior to CT in the detection of brain metastases, often detecting lesions that are not visible on CT. The use of PET/CT imaging is associated with better survival outcomes because metastases detected with PET/CT, which are not visible on standard CT, result in stage migration. Approximately 15% of patients with NSCLC[9,10] who are initially classified as stage I-III by CT will be upstaged to stage IV if PET/CT imaging is performed. These more advanced imaging tests can detect occult metastases in patients initially considered oligometastatic, thus obviating the application of aggressive local therapy in patients unlikely to benefit from treatment. In this regard, Tönnes et al[11] sought to determine whether the use of staging PET/CT in patients with NSCLC with a single surgically-resected metastasis had any influence on survival. Those authors compared patients who underwent surgery after preoperative staging with PET/CT (n = 66) vs conventional CT (n = 115). Five-year survival in the PET/CT group was 58% vs 33% in the conventional CT group (P = 0.01). It is important to note that the vast majority of published reports about oligometastatic NSCLC were conducted prior to the PET/CT era.

METASTASIS-DIRECTED LOCAL THERAPIES

Surgery has traditionally been the main treatment option in oligometastatic patients,
with approximately 55% of patients undergoing surgical resection[11]. However, the use of less invasive ablative techniques, principally stereotactic radiosurgery (SRS), has increased significantly in recent years. SRS, which was first used to treat brain metastases[12], involves the administration of ablative doses of radiation (delivered in one or more sessions) to the intracranial lesion. SRS is a highly precise technique that minimizes the dose to the surrounding healthy tissues. The application of SRS outside the brain is known as stereotactic ablative radiotherapy (SABR) or stereotactic body radiation therapy (SBRT). No studies have yet directly compared surgery to radiotherapy in oligometastatic disease. Moreover, many of the available studies have included patients who received both surgery and radiotherapy[13]. Although other ablative techniques, including radiofrequency ablation and cryoablation, have been used in oligometastatic patients, their role for this indication is limited and thus not discussed in the present review.

Treatment selection (i.e. surgery or radiotherapy) for oligometastatic patients will depend on several variables: Age; performance status; comorbidities; time of appearance of the metastases relative to the primary tumor (metachronous metastases have a better prognosis); number of lesions (prognosis is better in patients with a single metastasis); localization of the metastases (prognosis is better for metastases located in the brain, lung, and adrenal glands); extension of the primary tumor; and mediastinal lymph node involvement (better prognosis in stage N0 disease)[14]. It is important to interpret cautiously the results of the studies that have compared metastasis-directed treatments given the potential for selection bias due to the better prognosis of these patients (good performance status, technically operable, etc).

Surgery
Traditionally, surgical metastasectomy is the most common approach to oligometastatic NSCLC. The indication for surgery depends on various metastasis-related factors (size, number, and location of the metastases) and patient-specific factors (age, performance status, comorbidities, and prognosis). The strongest evidence supporting the benefits of surgical metastasectomy comes from studies involving patients with brain metastases. Patchell et al[15] randomized 48 patients (77% with NSCLC) with a single brain metastasis to receive either whole brain radiotherapy (WBRT) or surgical metastasectomy followed by WBRT. The results showed an increase in local control and OS in the surgically-treated group. Nevertheless, few studies have specifically evaluated the surgical resection of extracranial metastases in NSCLC. Of the studies that are available, most are retrospective and heterogenous, including patients treated a range of different radical intent approaches (surgery, SBRT, radiosurgery, or other ablative therapies)[16,17]. A study conducted in Germany[18] examined the role of surgery in NSCLC patients with synchronous, solitary metastatic lesions. At 5 years, OS was 38%; median survival was longer in patients without mediastinal lymph node involvement (50 mo vs 19 mo, P = 0.015). OS rates were better in patients with localized lung metastases compared to those with extrathoracic lesions (5-year OS: 48.5% vs 23.6%). Johnson et al[19] reported a 5-year OS rate of 58% in 22 patients with synchronous oligometastatic NSCLC without mediastinal node involvement who underwent surgery or radiotherapy to the primary tumor and metastases.

Radiotherapy
Several local ablative treatments, including radiotherapy, can be used to treat oligometastatic NSCLC. Technological advances of the last decade have made it possible to administer high ablative doses with great precision to various sites. Brain metastases are treated with SRS while SBRT is used for extracranial lesions. An important advantage of these high-dose treatments is that they require fewer fractions, and thus the treatment duration is shorter than with conventional fractionation schedules. SRS and SBRT are considered safe, with minimal treatment-related toxicity and only requiring a brief interruption of systemic therapy. In addition, ablative radiotherapy can be administered to all tumor sites throughout the body. Historically, surgical resection was the preferred local therapy for oligometastases in patients with NSCLC[20]. However, in many cases, these metastatic lesions are unresectable, or the patient is considered inoperable, or the long postoperative recovery period may require an unacceptable delay in the initiation of systemic therapy. As a result, less invasive treatments such as radiotherapy are often necessary. A recent survey (published in 2017) of more than 1000 radiation oncologists from 43 countries[17] found that the use of SBRT to treat oligometastatic NSCLC is growing. The most common pattern of recurrence in patients with oligometastatic NSCLC who undergo first-line systemic therapies is local recurrence alone[20]. This pattern of progression supports the application of aggressive local treatments to the primary tumor and the metastatic sites to increase PFS[21] and,
ultimately, OS. SBRT has proven beneficial in patients with a single metastasis as well as in those with multiple metastases\(^{29}\), with local control rates ranging from 70%-90% and grade (G) ≥ 3 toxicity rates less than 10%\(^{29}\). Hasselle et al\(^{20}\) investigated the role of SBRT in 25 patients with oligometastatic NSCLC (1-5 metastases). At a median follow-up of 14 mo, the median PFS and OS rates in that series were 7.6 and 22.7 mo, respectively. Several variables were associated with worse PFS: > two sites treated with SBRT; non-adenocarcinoma histology; prior systemic therapy; and progression after systemic therapy.

**PRINCIPAL STUDIES OF OLIGOMETASTATIC NSCLC**

**Retrospective studies**

One of the most important retrospective studies was carried out by López Guerra et al\(^{21}\). From January 2000 through June 2011, 78 consecutive patients with oligometastatic NSCLC (< 5 metastases) at diagnosis underwent definitive radiochemotherapy (≥ 45 Gy) to the primary tumor. Most of these patients (61/78; 78.2%) had only a single metastatic lesion, most (42%) located in the brain. The oligometastases were treated with local therapy in 44 patients (56%). The 2-year OS in the full cohort was 32%. Several variables were associated with improved OS: Tumor volume (gross tumor volume ≥ 124 cm\(^3\)), performance status, administration of ≥ 63 Gy to the primary tumor, and definitive local treatment of the oligometastases. Severe (grade ≥ 3) pulmonary and esophageal toxicity were observed in 6.4% and 19.4% of patients, respectively.

Another important retrospective study of oligometastatic NSCLC was performed by Mordant et al\(^{22}\). That study included 94 patients with NSCLC who had a solitary, extrathoracic synchronous metastasis. The primary tumor and metastases were treated surgically in all patients (69 of 94 metastases resected). The most common metastatic site was the brain (n = 57), followed by bone (n = 14), adrenal glands (n = 12), liver (n = 5), and skin (n = 5). Mediastinal node status was distributed as follows: N0 (n = 46), N1 (n = 17), and N2 (n = 32). The 5-year OS was 16% (median survival, 13 mo). Induction therapy, adenocarcinoma, N0 staging, and lobectomy were all associated with better prognosis, but surgical metastasectomy was not. These findings raise doubts about the superiority of surgical resection versus radiotherapy and/or chemotherapy as the treatment of choice for solitary synchronous M1b metastases.

During the 2006-2016 time period, several small (20 to 60 patients) retrospective studies\(^{23-25}\) of oligometastatic NSCLC were published. In those studies, both the primary tumor and the metastases received radical treatment (either surgery or radiotherapy). The median survival in those studies ranged from 13-22 mo, and the incidence of grade ≥ 3 toxicity was low.

Merino Lara et al\(^{26}\) recently reported results of a Canadian study involving 108 patients with metastatic NSCLC treated with extracranial SBRT for oligometastasis (n = 66), oligoprogression (n = 20), and local control of dominant tumors (n = 22). In the full cohort, median OS and PFS were, respectively, 27.3 and 4.4 mo. Patients treated with SBRT for oligometastasis presented longer OS and PFS (39.3 and 7.6 mo, respectively) than those treated for oligoprogression (21.1 and 3.3 mo, respectively) with better local control of dominant tumors (11.8 and 2.2 mo, respectively). The application of SBRT also delayed the time to starting/changing systemic therapy (SCST): Cumulative 1-year incidence = 21.5%. Predictors of time to SCST were: Tumor size ≤ 4 cm (1-year SCST: 11.3% vs 36.4% in tumors > 4 cm) and EGFR/ALK mutational status (1-year SCST in EGFR/ALK positive disease: 45.5% vs 16% in negative EGFR/ALK). The local failure rate at 1 year was 15.6%. Predictors of local failure at 1 year were tumor size (local failure: 7.7% in tumors ≤ 4 cm vs 26.6% in tumors > 4 cm) and treatment with previous systemic therapy (local failure without systemic therapy, 13.2% vs 17.7% with previous systemic therapy). Two patients developed grade ≥ 3 toxicity (respiratory events) and three patients developed radiation-induced bone fractures.

The Shanghai Pulmonary Hospital group\(^{27}\) evaluated 145 patients with stage IV EGFR-mutant NSCLC and ≤ 5 metastases at diagnosis. Of these patients, 35.2% received consolidative local ablative therapy (LAT) to all metastases (all-LAT group), 37.9% received LAT to the primary tumor or to the oligometastases (part-LAT group), and 26.9% did not receive LAT (non-LAT group). All patients received first-line anti-EGFR therapy (TKI). Median OS in the all-LAT, part-LAT, and non-LAT groups was, respectively, 40.9, 34.1, and 30.0 mo (P < 0.001). Median PFS was 20.6, 15.6, and 13.9 mo (P < 0.001), respectively. There was a significant difference in OS between the all-LAT group and the other groups, but no difference between the part-LAT and the non-LAT groups. Adverse effects (grade ≥ 3) included pneumonitis (7.7%) and
esophagitis (16.9%).

Another recent study conducted in Asia\textsuperscript{[29]} evaluated 231 patients with oligometastatic, EGFR-mutant lung adenocarcinoma treated with TKI alone (n = 88) or TKI plus local treatment of the metastases (n = 143). PFS (15 mo \textit{vs} 10 mo) and OS (34 mo \textit{vs} 21 mo) were both significantly better in the local metastasis-directed treatment.

**Clinical trials**

Several clinical trials, including two randomized phase II trials, have been conducted to evaluate the efficacy and safety of local ablative therapies (surgery or SBRT) in patients with oligometastatic NSCLC (Table 1).

A phase I/II trial\textsuperscript{[1]} assessed the efficacy and tolerability of SBRT (36 Gy in phase I and 60 Gy in phase II, delivered in 3 fractions) in 47 cancer patients (21.3% with lung cancer) who presented 1-3 liver metastases (63 lesions in total). Most (69%) of the patients had received at least one (range, 0 to 5) previous systemic treatments for metastatic disease, and 45% had extrahepatic disease at study inclusion. Median follow-up was 16 mo. Only one patient (2%) developed toxicity ≥ grade 3. One- and 2-year local control rates after SBRT were 95% and 92%, respectively. The 2-year local control rate was 100% in patients with lesions ≤ 3 cm in diameter. Median OS was 20.5 mo.

In 2012, Salama \textit{et al}\textsuperscript{[29]} reported the results of a dose escalation (SBRT) trial involving 61 patients with one to five metastases (total: 113 metastatic lesions). Only 11 patients in that study had NSCLC. Median follow-up was 20.9 mo. Treatment tolerance was good. At 2 years, PFS and OS rates were, respectively, 22% and 56.7%. In the patients whose tumors progressed, most (72%) were oligoprogression (one to three metastases). Two-year OS was 60.3% in patients with metastases \textit{versus} 21.9% in patients with four to five metastases.

A prospective, single-arm, phase II trial\textsuperscript{[13,30]} evaluated the role of SBRT in 39 patients with oligometastatic NSCLC (≤ metastases). Most (74%) of the patients had local stage III disease, and 87% had a single metastasis, most commonly in the brain (44%). In 95% of the patients, the primary treatment included chemotherapy. Median OS and PFS were, respectively, 13.5 and 12.1 mo. At 3, 5, and 6 years, OS rates were 10.3%, 7.7%, and 5.1%, respectively; the corresponding values for PFS were 7.7%, 7.7%, and 2.5%. Only three patients (7.7%) developed local recurrence. The treatment was well-tolerated, with no cases of grade ≥ 3 toxicity.

Iyengar \textit{et al}\textsuperscript{[31]} conducted a phase II randomized clinical trial involving 29 patients with oligometastatic NSCLC, without EGFR or ALK mutations, who achieved partial response or stable disease after chemotherapy. Patients were randomized to maintenance chemotherapy alone (n = 15) or SBRT followed by maintenance chemotherapy (n = 14). The trial was closed prematurely after the interim analysis revealed a significant increase in PFS in the SBRT group (9.7 mo \textit{vs} 3.5 mo) \textit{versus} the chemotherapy alone group (P = 0.01). Toxicity was similar in both arms. There were fewer recurrences overall in the SBRT group.

In 2016, Gomez \textit{et al}\textsuperscript{[32]} reported the results of a prospective, multicenter, randomized phase 2 study involving 74 patients with oligometastatic NSCLC (≤ 3 metastases). All patients received standard first-line systemic therapy consisting of chemotherapy and EGFR or ALK inhibitors. Patients with ≤ 3 metastases after systemic therapy were randomized to receive either local consolidation therapy (LCT) with surgery +/- radiotherapy to the primary tumor and metastases, with or without maintenance treatment or maintenance treatment (including observation, at the clinician’s discretion) alone. The patient groups were comparable with regards to lymph node involvement, EGFR/ALK status, response to first-line systemic therapy, brain metastases, and number of metastases. The study was closed after the first interim analysis (49 patients recruited) due to the treatment efficacy observed in the experimental arm. At a median follow-up of 13.9 mo, the study achieved the main objective: A statistically significant increase in PFS in the 25 patients who received LCT (11.9 mo) \textit{versus} the 24 patients in the non-LCT group (3.9 mo, P = 0.0054). In addition, time to the appearance of a new lesion was longer in the LCT arm (11.9 mo \textit{vs} 5.7 mo, P = 0.0497), suggesting that LCT may have altered the natural course of the disease, either by limiting the potential for subsequent dissemination or by altering systemic anticancer immune responses to facilitate longer control of subclinical disease. Adverse events were similar in the two groups, with no treatment-related grade 4 adverse events or deaths. The lead author of that study presented updated results at the American Society for Radiation Oncology congress in 2018\textsuperscript{[28]}. At a median follow-up of 38.8 mo, the PFS benefit was durable, with a median PFS of 14.2 mo in the LCT arm \textit{versus} 4.4 mo in the maintenance therapy/observation arm (P = 0.014). The extended follow up also demonstrated that LCT improved OS, with a median OS of 41.2 mo in the treatment arm \textit{versus} 17.0 mo in the control arm (P =
Table 1  Prospective trials of local treatment in oligometastatic disease

| Author                  | n  | Primary site, n | Treatment groups | Type of treatment | Endpoints                                      | Toxicity       |
|-------------------------|----|----------------|-----------------|------------------|------------------------------------------------|----------------|
| Rusthoven et al[1], 2009| 47 | CRC: 15; Lung: 10; breast: 4; other: 10 | SBRT            | Phase I: 36-60 Gy in 3 fx; Phase II: 60 Gy in 3 fx. | LC 2 yr: 92%; OS 2 yr: 30%                       | G3: 2%; No RILD |
| Salama et al[18], 2011  | 61 | NSCLC: 11; SCLC: 5; H&N: 5; Other: 40 | SBRT            | 3 fx: 8 Gy 3 fx: 20 Gy | MFu: 20.9 mo; PFS 2 yr: 22%; OS 2 yr: 56.7%     | G3 (n = 2)     |
| Iyengar et al[39], 2014 | 24 | NSCLC            | SBRT + erlotinib | SBRT + erlotinib | MFu: 11.6 mo; PFS: 14.7 mo; OS: 20.4 mo         | G3 (n = 2); G4 (n = 1); (after SBRT to three sites) |
| Collen et al[10], 2014  | 26 | NSCLC            | SBRT after primary treatment | 50 Gy in 10 fx | MFu: 16.4 mo; PFS 1 yr: 45%; median 11.2 mo; OS 1 yr: 67% | G2: 15% G3: 8% (n = 2) |
| Gomez et al[36], 2018   | 49 | NSCLC            | LCT (CRT/Surgery of all lesions) vs maintenance therapy/obs. | SBRT n = 5; Surgery n = 3; pemetrexed n = 2; afatinib n = 1, bevacizumab | Median PFS: 14.2 mo/4.4 mo (P < 0.05); Median OS: 41.2 mo/17.0 mo (P < 0.05) | Similar, G3   |
| Iyengar et al[39], 2018 | 29 | NSCLC            | Maintenance Ct alone vs SBRT followed by maintenance Ct | Ct: carboplatin + pemetrexed; SBRT: 1, 3 and 5 fractions with 21-27 Gy, 26.5-33 Gy and 30-37.5 Gy respectively | MFu: 9.6 mo Median PFS: Ct: 3.5 mo - SBRT: 9.7 mo (P < 0.05); Median OS: no difference | G3 n: 4 vs 2; G4 n: 1 (ct only); G5 n: 3 vs 6. No grade 3 or higher toxicity attributable to SBRT |
| De Ruyscher et al[4], 2018 | 40 | NSCLC            | Primary: RT or CRT, LCT (surgery, SBRT) | SBRT: 54 Gy of bone metastases. CNS: 1 fx: 8-20 Gy single or 24 Gy × 3 fx. PORT: 60 Gy | Median OS: 13.5 mo; 2 yr OS: 23.3%; 10.3% Median PFS: 12.1 mo; 2 yr PFS: 51.3%-2.5% | G3 esophagitis: 15%; > G4: 0% |

CRC: Colorectal cancer; NSCLC: Non-small cell lung cancer; SCLC: Small cell lung cancer; CNS: Central nervous system; ECOG: Eastern Cooperative Oncology Group; P/PORT: Postoperative radiotherapy; PFS: Progression-free survival; MFu: Median follow up; OS: Overall survival; LCT: Local consolidative therapy; Ct: Chemotherapy; RT: Radiotherapy; fx: Fraction; CRT: Chemoradiotherapy; SBRT: Stereotactic body radiotherapy; LCT: Local control; RILD: Radiation-induced liver disease; H&N: Head and neck.

0.017). No additional grade 3 or higher toxicities were observed in either arm. This was the first randomized clinical trial to demonstrate an increase in OS in patients with oligometastatic NSCLC. The main limitations of the study were the limited sample size, molecular heterogeneity (including EGFR and ALK patients), and the definition of oligometastatic disease (which was defined after systemic therapy).

In the American Society for Radiation Oncology 2018 congress, Palma et al[43] presented results of the international (Australia, Canada, Scotland, and Netherlands) SABR-COMET trial that included 99 patients with oligometastatic cancer treated from 2012 to 2016. All of the patients had good performance status (Eastern Cooperative Oncology Group (ECOG) 0-1). The most common primary tumor types were breast (n = 18), lung (n = 18), colorectal (n = 18), and prostate (n = 16) cancer. The inclusion criteria allowed for up to 5 metastatic lesions, although 93% had only 1-3 lesions. Median age was 68 years, and 59% of the patients were men. Patients were randomized 2:1 to SABR plus standard palliative care (treatment group) or palliative care alone (control arm). The baseline characteristics of the two groups were comparable. Some of the patients who developed new metastatic lesions during the trial were successfully treated with additional ablation therapy. At a median follow-up of 27 mo, median PFS was 12 mo in the treatment group versus 6 mo in the control arm (P = 0.001). At 5 years, 46% of patients in the SABR arm remained alive versus only 24% in the control arm. The median OS was numerically better in the SABR group: 41 mo [95% confidence interval (CI), 26 mo to “not reached”] versus 28 mo (95%CI: 19-33 mo) in the control group (P = 0.09). Adverse events (AEs) ≥ grade 2 were more common in the SABR group (30% vs 9%). The most common AEs were fatigue, dyspnea, and pain (muscle, joint, bone, or other types). Three AE-related deaths occurred in the investigational arm. No differences in quality of life were observed. At 6 mo post-treatment, overall scores on the Functional Assessment of Cancer Therapy General questionnaire were high in both the SABR and control arms: 82.5 versus 82.6, respectively (P = 0.992). No significant between-group differences were observed on the functional, emotional, physical, and social subscales of the Functional Assessment of Cancer Therapy General. A follow-up phase III study (SABR-COMET-3) will evaluate this treatment approach in patients with up to three
Median survival according to DS-GPA values are as follows: 0-1: 3 mo; 1.5-2: 5.5 mo; and N1/N2 disease (5-year OS, 13.8%).

Metastases and N0 disease (5-year OS, 36.2%); and high risk: Metachronous metastases (5-year OS, 47.8%); intermediate risk: Synchronous metastasis, N-stage, and a non-adenocarcinoma histology. Patients were stratified into three prognostic groups based on an analysis of the study data: Low-risk: Metachronous metastases and N1/N2 disease (5-year OS, 13.8%); intermediate risk: Synchronous metastases and N0 disease (5-year OS, 36.2%); and high risk: Synchronous metastases and N1/N2 disease (5-year OS, 47.8%).

The timing of the appearance of metastases is another important prognostic factor evaluated in the meta-analysis by Ashworth et al[9], which included a total of 757 patients with oligometastatic (one to five metastases) NSCLC. The metastases were synchronous in 75.5% of patients and metachronous in the other 24.5%. Treatment consisted of ablative therapy (mainly surgery) plus curative-intent treatment of the primary tumor. The median patient age was 61.1 years. Most patients had good performance status. The majority of patients (96.5%) had only one or two metastases. Median OS was 26 mo. The following factors were associated with worse OS: Number of metastases; mediastinal node involvement; time until onset of metastases (DFI > 6 mo); histology; age; performance status; diagnosis-specific graded prognostic assessment (DS-GPA classification)[5] in patients with brain metastasis; pathological T-staging; the metastatic location (brain or adrenal glands versus other locations); treatment of the primary tumor (the type of surgical resection, intrathoracic small radiotherapy treatment volumes); and the molecular profile.

Although nearly all of the studies to date have included patients with up to five metastases, most of those patients had three or fewer metastases. Moreover, half of the patients in the meta-analysis by Ashworth et al[9] had only a single metastasis. In general, prognosis is better in patients with few metastases versus those with multiple metastases, regardless of whether metastasis-directed therapy is administered or not[2]. In this regard, the study by Albain et al[3] is worth highlighting. They evaluated 2531 patients with disseminated NSCLC, finding better OS in patients with a single metastasis (8.7 mo) versus those with multiple metastases in a single organ (6.2 mo) versus patients with multiple metastases in multiple organs (5.1 mo). Similar results were obtained by the International Association for the Study of Lung Cancer [3] in a validation study conducted in the context of preparing the 8th edition of the American Joint Committee on Cancer staging manual. In that study, OS was longer (median, 17.8 mo) in patients with a single extrathoracic metastasis than in those with multiple metastases (13.6 mo, P < 0.001).

Mediastinal node involvement is an important adverse prognostic factor for OS in patients with oligometastatic NSCLC. In this regard, a study of 39731 patients with M1a NSCLC included in the Surveillance, Epidemiology, and End Results database demonstrated that patients without lymph node involvement had the best cancer-specific survival, followed by patients with N1 disease; there were no differences in cancer-specific survival between patients with N2 or N3 disease[4].

The timing of the appearance of metastases is another important prognostic factor evaluated in the meta-analysis by Ashworth et al[9], which included a total of 757 patients with oligometastatic (one to five metastases) NSCLC. The metastases were synchronous in 75.5% of patients and metachronous in the other 24.5%. Treatment consisted of ablative therapy (mainly surgery) plus curative-intent treatment of the primary tumor. The median patient age was 61.1 years. Most patients had good performance status. The majority of patients (96.5%) had only one or two metastases. Median OS was 26 mo. The following factors were associated with worse OS: Synchronous metastasis, N-stage, and a non-adenocarcinoma histology. Patients were stratified into three prognostic groups based on an analysis of the study data: Low-risk: Metachronous metastases (5-year OS, 47.8%); intermediate risk: Synchronous metastases and N0 disease (5-year OS, 36.2%); and high risk: Synchronous metastases and N1/N2 disease (5-year OS, 13.8%).

In patients with brain metastases, predictors of survival include performance status, extent of extracranial disease, patient age, and number of brain metastases. This is known as the diagnosis-specific graded prognostic assessment (DS-GPA).

Median survival according to DS-GPA values are as follows: 0-1: 3 mo; 1.5-2: 5.5 mo;
In a retrospective study of 168 patients with oligometastatic NSCLC (≤ 5 lesions), Parikh et al.[25] assessed the role of performance status and histology on outcomes, finding that N2-3 nodal status was an unfavorable prognostic factor. In that study, ECOG performance status ≥ 2, squamous cell histology, and metastases to multiple organs were all associated with a greater risk of death. By contrast, definitive local therapy to the primary tumor was associated with prolonged OS.

The role of pathologic T-stage on treatment outcomes was evaluated in a retrospective study of 29 patients with synchronous, single-organ metastatic NSCLC treated by lung resection and metastasis-directed therapy. Median survival was 20.5 mo, with a 5-year OS of 36%. Pathologic T stage was a predictor of survival. Median survival was significantly longer in patients with pT1-2 disease (26 mo) versus those with pT3-4 disease (8 mo, \( P = 0.007 \)).

The site of the metastatic lesion is another important prognostic factor. Lung, brain, and adrenal gland metastases appear to be associated with better survival than bone or liver metastases[26]. Griffen et al.[27] retrospectively evaluated 61 patients with one to three synchronous metastases treated with radical intent. Those authors found that the factors associated with improved survival after first progression were: Surgical excision of the primary lung tumor, presence of brain metastases (13.0 mo vs 3.3 mo, \( P = 0.002 \)), and absence of bone metastases (11.9 mo vs 3.3 mo, \( P = 0.004 \)). The study conducted to validate that finding that the newly-proposed M staging classification system included a total of 1024 patients with stage IV NSCLC, showing that patients with lung metastases (M1a) had a better prognosis than those with extrathoracic metastases (M1a: 22.5 mo vs M1b: 17.8 mo vs M1c: 13.6 mo, \( P < 0.001 \)).

Franceschini et al.[28] recently evaluated patient-, treatment-, and disease-related variables that could potentially predict response to SBRT and survival. That study included 358 oligometastatic patients (≤ 5 lesions to three or fewer sites) from different primary tumors (23.7% NSCLC). At a median follow-up of 31.8 mo, 6- and 24-mo local control rates were, respectively, 94.6% and 78.9%; the corresponding PFS rates were 66.1% and 18.4%. Median OS was 34.7 mo (95% CI: 29.6-43.8), and 6- and 24-mo OS rates were 96% and 63.5%, respectively. On the multivariate analysis, pulmonary and nodal metastases were both associated with longer OS. Local response was also associated with OS. By contrast, primary lung cancer, older age, and metastases in locations other than those irradiated were all independent predictors of shorter OS.

Frost et al.[29] conducted a retrospective propensity score analysis of 180 patients with synchronous oligometastatic (≤ 4 metastases) lung cancer (including NSCLC and neuroendocrine lung cancer) who received local treatment (surgery or SBRT) to all metastatic sites (experimental group) or standard chemotherapy combined, if needed, palliative-intent local treatment (control group). The experimental group had significantly better PFS (25.1 mo vs 8.2 mo, hazard ratio (HR) = 0.30, 95% CI: 0.21-0.43, \( P < 0.001 \)) and OS (60.4 mo vs 22.5 mo, HR = 0.42, 95% CI: 0.28-0.62, \( P < 0.001 \)). The most important prognostic factor was local treatment of the metastases. Several variables were associated with better PFS: adenocarcinoma histology, stage T1a, lymph node stage (N0-2 vs 3), and single versus multiple metastases. Performance status (ECOG 0-1 vs 2) was associated with better OS.

The meta-analysis conducted by Li et al.[30] examined 24 studies (clinical trials and comparative retrospective studies) to identify prognostic factors in oligometastatic NSCLC. A total of 1935 patients were included. On the univariate analysis, neither age, nor smoking status, nor type of metastasis had any influence on OS. By contrast, several variables were significant prognostic factors for OS: Female sex (HR = 1.21, 95% CI: 1.02-1.45, \( P = 0.03 \)), stage pN0 (HR = 1.82, 95% CI: 1.40-2.36, \( P < 0.00001 \)), and adenocarcinoma (HR = 1.44, 95% CI: 1.10-1.88, \( P = 0.008 \)). On the multivariate analysis, stage pN0 disease was associated with significantly better OS compared to stage pN1 disease (HR = 1.63, 95% CI: 1.27-2.10, \( P = 0.001 \)) but not when compared to stage pN2 disease (HR = 2.01, 95% CI: 0.80-5.03, \( P = 0.14 \)). In the subgroup analyses, none of the following variables had a significant impact on OS: thoracic stage, primary tumor, tumor histology, or number of oligometastases. However, patients who received aggressive/radical local treatment of the primary tumor had better OS (HR = 0.56, 95% CI: 0.37-0.83, \( P = 0.001 \)), as did patients who received aggressive/radical local treatment of the oligometastases (HR = 0.54, 95% CI: 0.36-0.82, \( P < 0.00001 \)).

The molecular profile of the patients also appears to be a prognostic factor associated with survival. Lussier et al.[31] identified a specific microRNA expression that identified the patients most likely to remain oligometastatic after metastasis-directed treatment and therefore associated with a better prognosis.
SPECIFIC SITUATIONS

Brain oligometastases

Lung cancer is the main source of brain metastases, and 25%-30% of lung cancer patients present brain metastases at diagnosis. In certain cases, radical management of these metastases is associated with better outcomes: Limited number of metastases, good performance status, and favorable histology. The main treatment approaches for this indication are surgery, WBRT, and SRS (Figure 1).

Data from retrospective case series show that patients with NSCLC with a single synchronous brain metastasis who undergo radical treatment of the primary tumor and the brain metastasis have better OS (7%-24% at 5 years). One of the first and most important studies was conducted by Patchell et al[4], who carried out a prospective randomized trial involving patients (77% with NSCLC) with a single brain metastasis treated by surgery or surgery-WBRT. The surgery-WBRT arm had a better OS with a lower rate of recurrence (18% vs 70%).

SRS is another treatment option in this postoperative scenario. In 2017, Lamba et al[5] carried out a meta-analysis of retrospective studies, finding that SRS of the surgical cavity appears to yield survival outcomes and local and distant control rates that are comparable to WBRT. In a recent phase III trial, Mahajan et al[6] randomized patients (n = 128) who had undergone complete resection of one to three brain metastases to either observation or SRS. Those authors observed no local recurrences in 72% of the SRS group versus 43% of the observation group. This finding supports the use of SRS as an alternative to postoperative WBRT in this patient profile. In non-surgical patients, the RTOG 9508 phase III clinical trial evaluated 331 patients with one to three brain metastases from different primary tumors (64% lung cancer). The patients were randomized to receive either WBRT or WBRT plus an SRS boost to all lesions. On the univariate analysis, there was a survival benefit for the SRS boost only in the patients with a single brain metastasis (mean survival, 6.5 mo vs 4.9 mo, P = 0.0393).

An important consideration in the treatment of brain oligometastases is the need to avoid the neurocognitive morbidity associated with WBRT. A randomized trial of 132 patients with up to four brain metastases (maximum diameter, 3 cm), compared SRS alone to SRS-WBRT and reported similar survival outcomes (8 mo vs 7.5 mo), indicating that patients with brain oligometastases could be treated with SRS alone[7]. Bhatnagar et al[8] evaluated the results of SRS alone in 205 patients (42% with NSCLC) with four to fifteen brain metastases. The 1-year local control rate was 71%, with a mean OS of 8 mo. The total treatment volume was a better predictor of survival than the number of metastases, a finding that raised the possibility that the concept of brain oligometastasis may be more closely associated with tumor volume than with the number of lesions. The recent meta-analysis by Tsao et al[9] compared WBRT to SRS-WBRT and SRS to WBRT-SRS, finding that combined treatment offers no OS benefit compared to SRS alone. While WBRT improved local control, toxicity with SRS was much lower[10].

There are no randomized trials comparing surgery-WBRT to SRS-WBRT, although one phase III trial compared surgery-WBRT to SRS for the treatment of single brain metastasis (≤ 3 cm in diameter). Although that study was closed early due to low recruitment, there were no significant survival differences between the two groups (64 patients)[11].

There is some controversy surrounding the optimal management of NSCLC patients with brain metastases who present an actionable oncogenic driver mutation (e.g., EGFR or ALK). Different phase III trials with third-generation anti-EGFR/ALK TKI, with ability to cross the blood-brain barrier, have shown CNS (central nervous system) response rates of up to 80% and an increase in OS[12]. The greater efficacy to treat CNS diseases raises the option of treating these patients with TKI alone, thus allowing for a delay in radiotherapy until progression is detected. However, there are still no randomized studies comparing these strategies directly and prospectively. On the other hand, Magnuson et al[13] reported results of a multi-institutional analysis of 351 patients treated with SRS followed by EGFR-TKI or WBRT followed by EGFR-TKI, or EGFR-TKI followed by SRS or WBRT upon intracranial progression. There were significant differences among the three groups in median OS: 46, 30, and 25 mo, respectively (P < 0.001), showing better results with the early local treatment.

Adrenal oligometastasis

The lung is the main site of origin for most adrenal gland metastases. The incidence of these lesions has increased in recent years due to the increasing use of PET-CT and MRI. Unilateral involvement is more common when no other metastases are present (50% of cases); however, if metastatic involvement is present in other sites, unilateral adrenal involvement is only observed in 25% of cases. Traditionally, adrenalectomy...
Figure 1 Stereotactic body radiation therapy dose distribution for a single brain metastasis from non-small cell lung cancer. Planning computed tomography fused with magnetic resonance images. A: Coronal view; B: Axial view; C: Sagittal view.

has been the treatment of choice in selected patients[63]. The results of laparoscopic surgery are equivalent to open surgery, with less morbidity[64].

Recently, SBRT has become an excellent alternative to surgery for the treatment of adrenal oligometastasis[65] (Figure 2). Published case series, most with > 12 mo of follow-up, suggest that toxicity ≥ G2 is practically nonexistent. Moreover, the excellent local control rates (> 90%) are highly promising. Probably the most notable case series published to date is the 34 patient series reported by Scorsetti et al[66]. This study has the longest median follow-up to date (41 mo), with excellent local control rates (93%).

Holy et al[67] reported a median OS of 23 mo, comparable to surgical series, in patients with NSCLC with a single adrenal metastasis treated with SBRT (40 Gy in five fractions). Casamassima et al[68] reported results from a series of patients with adrenal metastases from different primary tumors (including NSCLC). Those patients received SBRT (36 Gy in three fractions), obtaining a 2-year local control rate of 90%. To date, a range of different fractionation schedules and doses have been used to treat adrenal gland metastases. Some authors, such as Li et al[69], have proposed a biologically-effective dose (BED) 10 > 100 Gy (as in other metastatic sites), suggesting that this BED provides greater local control.

The ideal candidate for radical intent local treatment to the adrenal metastasis remains to be defined. Similarly, we still need to define the optimal treatment, either surgery or SBRT. Given the lack of comparative studies, current evidence suggests that SBRT yields comparable local control rates to surgery, with less morbidity and lower mortality rates. Moreover, SBRT is easier to combine with systemic treatment.

Liver oligometastases
While liver metastasis is less common than in other locations in patients with NSCLC, the presence of such lesions is an unfavorable prognostic factor[5]. Although surgery remains the treatment of choice for these lesions, estimates suggest that only 10%-20% of patients are eligible for surgery[70]. Several different ablative techniques have been investigated, with reported local control rates as high as 90%-100%. However, these ablative treatments are limited by the patient’s reserve of healthy liver tissue, the risks of bleeding, lesion size, and the presence of nearby vascular structures[73]. SBRT has become a non-surgical option in these patients (Figure 3).

Numerous retrospective and prospective studies have evaluated SBRT for liver oligometastases, all of which have included patients with liver metastases from different primary tumors (Table 2). Of these, the recent study carried out by Mahadevan et al[74] stands out. They evaluated 427 patients with a total of 568 liver metastases (12% secondary to lung cancer) treated with SBRT. OS was longer (25 mo vs 15 mo) in small volume metastatic lesions (< 4 cm) and in lesions that received a BED 10 ≥ 100 Gy (27 mo vs 15 mo), which also yielded better local control (77.2% vs 59.6%). Tumor histology had no impact on local control rates. While we await the results of ongoing prospective studies, the available evidence indicates that the high local control rates obtained with SBRT appear to be similar to those achieved with other local treatments, with a good toxicity profile.

Lung oligometastases
Surgical resection of lung metastases has a long history. The influential “Analysis of the International Registry of Pulmonary Metastases” was published in 1997[75]. In that study, 5206 cases of pulmonary metastases (of various different histologies) were
evaluated, showing 5- and 15-year OS rates of 36% and 22%, respectively. The following were independent prognostic factors: Number of metastases, complete resection, and long DFI. Pulmonary metastases secondary to lung cancer are one of the most common metastatic locations. However, only a minority of patients are candidates for surgery. Local control rates range from 85%-95% after lobectomy and from 50%-70% after wedge resections\[83,84\].

A meta-analysis of 757 patients with oligometastatic NSCLC found that, among patients who underwent radical-intent local treatment, survival was better in those who had metachronous versus synchronous disease (P < 0.001)\[6\]. Various series have shown that survival rates achieved with lobectomy or pneumonectomy are comparable to sublobar resection but with greater morbidity\[85,86\].

In recent years, SBRT has become an excellent alternative to surgery for this indication (Figure 4). Rusthoven et al\[7\] carried out a phase I/II trial to evaluate the efficacy and tolerability of SBRT in patients with one to three lung metastases (≤ 7 cm in diameter). Radiotherapy was delivered in three fractions, and the dose was safely escalated from 48 to 60 Gy in phase I. The study included 38 patients (13.2% with primary NSCLC) and 63 metastatic lesions. Most (71%) of the patients received systemic treatment. The incidence of G3 toxicity was 8%, with no cases of G4 toxicity. Local control rates at 1 and 2 years were 100% and 96%, respectively. In the Mayo Clinic study carried out by Milano et al\[87\], 121 patients with ≤ 5 metastases of differing histologies (including NSCLC) received SBRT to all metastatic lesions. At 2 years, local control was 74% in patients with non-breast cancer tumor histologies, and mean survival was 18 mo. OS was longer in patients with a clinical response or stable disease after systemic treatment administered prior to SBRT. Iyengar et al\[88\] performed a randomized trial to assess SBRT in patients with oligometastatic NSCLC. SBRT was administered in one (19-24 Gy), three (27-33 Gy), or five sessions (35-40 Gy). All metastases (up to six extracranial lesions) were irradiated and patients received concurrent erlotinib after progression following first-line chemotherapy. PFS and OS were, respectively, 14.7 and 20.4 mo, which was higher than that from previous reports in patients who developed progression to first-line treatment without SBRT. A retrospective analysis at the University of Chicago included 25 patients (62 lesions) diagnosed with oligometastatic NSCLC (one to five lesions). At a mean follow-up of 14 mo, DFS and OS were, respectively, 7.6 and 22.7 mo\[89\]. The aforementioned study by Gomez et al\[32\] and Gómez et al\[33\] are among the most important conducted to date in oligometastatic NSCLC. Of the 25 patients who received local consolidative therapy after systemic treatment, 23 cases involved the lung, which is therefore the most important site in this study.

To date, no randomized trials have directly compared SBRT to surgery in the treatment of lung metastases. However, based on the currently available results of both treatments, SBRT seems to be the better option due to greater patient tolerability and because it is easier to combine with systemic treatment. Pending comparative results, the two treatments appear to provide similar local control.

Oligometastases in other localizations

The use of local treatment is growing as is the number of oligometastatic possible sites\[9\]. Local therapy is now used to treat oligometastatic lesions in the bones, the spinal cord, and lymph nodes. Surgery has long been the treatment of choice for bone metastases in selected patients. However, due to the significant morbidity and mortality associated with surgery, the indications for this approach in bone.
metastases are limited\textsuperscript{[89]}. The evidence base to support spinal cord or lymph node surgery in oligometastatic NSCLC is limited, which is why surgery is only indicated in cases in which a consensus decision by a multidisciplinary team has been reached after evaluating other therapeutic options.

The growing and increasingly effective use of local treatment of oligometastatic lesions is primarily due to the emergence of SBRT. Several recent reviews have evaluated the available body of evidence, mainly case series, for SBRT in these three metastatic sites (2, 3, and 4)\textsuperscript{[90-92]}. Most of the studies published to date share several characteristics. For example, they all include patients with metastases to various sites, with differing histologies, treatment schemes, and a good tolerance profile (with exceptionally low rates of G3-4 toxicity). Moreover, in most published series, local control rates generally range from 80%-85% (or higher). Pending the publication of prospective studies, the decision to administer local treatment to these sites must be based on a consensus agreement among specialists after a thorough evaluation of the patient and careful consideration of the optimal local treatment.

**MANAGEMENT OF THE PRIMARY TUMOR IN OLIGOMETASTATIC NSCLC**

Management of the primary tumor in patients with oligometastatic NSCLC should be evaluated individually and based on the available evidence. Currently, as we can see in previous sections, the most robust evidence is for patients diagnosed with synchronous intracranial metastases (one to three lesions). There is some evidence suggesting that treatment of the primary thoracic tumor and mediastinal lymph nodes in oligometastatic patients is associated with better survival, as shown in the studies discussed previously\textsuperscript{[6,37,38,41]}. Li et al\textsuperscript{[93]} performed a meta-analysis of seven retrospective, observational cohort studies involving 668 synchronous oligometastatic NSCLC patients. Of those 668 patients, 227 (34.0\%) received aggressive thoracic therapy (surgery and/or radiotherapy, total dose > 40 Gy). Aggressive thoracic therapy was associated with a significant improvement in OS in the full cohort (HR = 0.48, \( P < 0.00001 \)) and in three subgroups: Patients with metastases to a single organ (HR = 0.42), those with a solitary brain metastasis (HR = 0.49), and patients with stage I-II thoracic disease (HR = 0.38). In addition, 4-year OS rates were significantly higher in patients who received aggressive thoracic therapy (12.6\% vs 2.0\%). Several studies have shown that definitive treatment of the primary tumor is a favorable prognostic factor for survival in NSCLC, as reflected in the results of the meta-analysis conducted by Ashworth and colleagues\textsuperscript{[6]}. The main treatments for the primary tumor are surgery, primarily lobectomy, and radiotherapy, with or without chemotherapy (depending on the disease stage). Radiotherapy can be normofractionated or hypofractionated (SBRT) in patients with negative node disease, which is a favorable prognostic factor.

In their case series, Lopez Guerra et al\textsuperscript{[22]} evaluated prognostic factors in oligometastatic lung cancer, finding that small tumor volumes, radiotherapy doses > 63 Gy, and good functional status were all associated with better survival. Similarly, Griffoen et al\textsuperscript{[25]} retrospectively analyzed 61 patients, finding that small radiation volumes and surgical treatment of the primary tumor were both prognostic factors for better survival.
Recently, two interesting studies have been published to evaluate the role of irradiating the primary tumor in oligometastatic NSCLC. In the first one, Petrelli et al.\textsuperscript{[94]} conducted a systematic review and meta-analysis of all published prospective trials and retrospective studies (up to July 2018) that compared radiotherapy versus no radiotherapy to the primary lung tumor in patients with synchronous oligometastatic NSCLC. A total of 924 patients from 21 studies were included. Patients who received thoracic irradiation of the primary tumor had significantly better OS (HR = 0.44, 95%CI: 0.32-0.6, \(P < 0.001\)) and PFS (HR = 0.42, 95%CI: 0.33-0.55, \(P < 0.001\)). The second study conducted by Arrieta et al.\textsuperscript{[95]} is a phase II prospective trial to evaluate patients (\(n = 37\)) diagnosed with stage IV NSCLC with \(\leq 5\) synchronous metastases at any location, including the CNS. All patients received four cycles of systemic treatment. The metastases and primary tumor were both irradiated in patients who responded (stable disease or partial response) to systemic therapy. Nineteen patients (51.4\%) showed a complete response (CR) to radiotherapy on PET-CT imaging. The PFS for the full cohort was 23.5 mo (95%CI: 13.6-33.3). OS was better in the patients with CR on PET-CT, leading the authors to conclude that CR is an important prognostic factor.

### LOCAL TREATMENT COMBINED WITH SYSTEMIC THERAPY

Although nowadays treatment of oligometastatic NSCLC with a radical intention is a routine practice, the optimal treatment sequence remains controversial because the data to support this recommendation come mostly from retrospective or small prospective studies. Therefore an individualized assessment of every patient is necessary to develop a radical-intent treatment plan and should always be determined by a multidisciplinary team. Several factors must be considered, including: Local extension of primary tumor, the tumor type (presence or absence of target mutations); the number, size and location of the metastases; the time of diagnosis (\textit{i.e.} synchronous vs metachronous), and other patient-related factors such as the presence or absence of symptoms secondary to the disease, performance status, and comorbidities. Importantly, there are no clear criteria available to guide patient

---

**Table 2** Published results for stereotactic body radiation therapy-treated liver metastases

| Study                  | Number of lesions | Patients, \(n\) | Primary tumor | Dose/fraction | Toxicity                              | Mean follow-up, mo | Control, local | Survival |
|------------------------|-------------------|-----------------|---------------|---------------|---------------------------------------|--------------------|----------------|----------|
| Blomgren et al.\textsuperscript{[74]} | Variable          | 31              | Various       | 8-66 Gy/1-4   | 2 Hemorrhagic gastritis               | 1.5-3.8            | 80%           | Not reported |
| Hoyer et al.\textsuperscript{[75]}   | 1-6 (< 6 cm)      | 44              | Various       | 45 Gy/3       | 1 liver failure 2 severe GI toxicity  | 52                 | 2-yr: 86%     | 1-yr: 67% 2-yr: 38% |
| Mendez Romero et al.\textsuperscript{[76]} | 1-3 (< 7 cm)      | 25              | Various       | 37.5 Gy/3     | 4 acute grade 3 3 late grade 3        | 12.9               | 2-yr: 86%     | 1-yr: 85% 2-yr: 62% |
| Rusthoven et al.\textsuperscript{[77]} | 1-3 (< 6 cm)      | 47              | Various       | 60 Gy/3       | < 2% late 1 liver failure 2 severe GI toxicity | 16                 | 2-yr: 92% < 3 cm: 100% | mean: 17.6 mo |
| Lee et al.\textsuperscript{[78]}     | Variable          | 68              | Various       | 28-60 Gy/3    | Acute: 8 GIII, 1 GIV                    | 10.8               | 2-yr: 86%     | 1-yr: 71% 2-yr: 47% |
| Ambrosino et al.\textsuperscript{[79]} | 1-3 (< 6 cm)      | 27              | Various       | 25-60 Gy/3    | Not reported                           | 13                 | 74%           | Not reported |
| Goodman et al.\textsuperscript{[80]} | 1-5 (< 5 cm)      | 26              | Various       | 18-30 Gy/1    | Late: 4 GII                            | 17.3               | 1-yr: 77%     | 1-yr: 62% 2-yr: 49% |
| Rule et al.\textsuperscript{[81]}    | 1-5               | 27              | Various       | 30 Gy/3 50-60 Gy/5 | No ≥ G2                              | 20                 | 30 Gy: 56% 50 Gy: 89%60 Gy: 100% | 30 Gy: 56% at 2-yr 50 Gy: 67% at 2-yr 60 Gy: 50% at 2-yr |
| Scortetti et al.\textsuperscript{[82]} | 1-3 (< 6 cm)      | 61              | Various       | 52.5-75/3     | No ≥ G3                               | 24                 | 91%           | 1-yr: 80%2-yr: 70% |
| Mahadevan et al.\textsuperscript{[83]} | Variable          | 427             | Various       | 45 (12-60) / 3 (1-5) | Not reported                           | 14 (1-91)          | Median: 52 mo 1-yr: 84%2-yr: 72% | Mean: 22 mo 1-yr: 74% 2-yr: 49% |

GI: Gastrointestinal.
selection nor is there an standard strategy to combine ablative local treatment with systemic therapy in this patient profile.

In patients who present with synchronous metastases at diagnosis, an accepted strategy is to initiate systemic treatment and then re-stage the patient to confirm disease response (i.e. absence of progression) before administering radical treatment to the primary tumor and metastases. This was the strategy used in the two phase II randomized trials, both of which found better PFS and OS in patients who received radical local therapy\(^{[31,33]}\).

A second strategy could be radical treatment of all metastatic lesions followed by systemic consolidation treatment. This approach was used by De Ruisscher et al\(^{[30]}\) in a phase II prospective trial with 39 patients. The results were poor, with a 5-year PFS of only 8\%, probably because this strategy does not include an option to select patients who respond to systemic therapy.

The use of more effective and less toxic treatments such as immunotherapy and targeted therapies has brought about a change in the natural history of NSCLC. There is a new subset of patients who present with oligoprogression during systemic treatment. In those patients, the local therapy of the progressive metastases is also associated with a longer PFS and OS while allowing continuation with the same systemic treatment\(^{[96,97]}\).

With regard to the treatment strategy in patients with metastatic involvement limited to the CNS, there is a stronger consensus in favor of initiating treatment with SRS or surgical resection. In the subgroup of patients with activating mutations (EGFR or ALK) with asymptomatic lesions, it is considered reasonable to initiate targeted therapy before radiotherapy\(^{[96-100]}\). However, SRS followed by EGFR-TKI, an approach used in the study by Magnuson et al\(^{[61]}\), is an alternative option to consider in these patients.

### RECOMMENDATIONS IN CLINICAL GUIDELINES

The oligometastatic state is based on the concept of long-term disease control, which is achieved through the aggressive local treatment of metastases. For this reason, clinical guidelines have already begun to incorporate local treatment techniques such as SBRT.

**Spanish Society of Medical Oncology**

The Spanish Society of Medical Oncology guidelines recommend local treatment (SBRT or surgery) in oligometastatic patients with up to five metastases, provided that all of lesions are susceptible to radical treatment\(^{[99]}\).

The guidelines define four different clinical scenarios eligible for local treatment: (1) Metastases limited in number and location at the time of diagnosis. These metastases and the primary tumor must be susceptible to local treatment; (2) Limited number of metastases after primary treatment. All lesions must be susceptible to radical treatment; (3) Limited number of metastases that progress after systemic treatment; primary tumor and the other metastases remained controlled; and (4) Oligo-recurrence in patients who received radical-intent treatment, with one to five metachronous metastases susceptible to radical treatment.

The guidelines recommend that patients with oligometastatic disease at diagnosis receive radical treatment with systemic therapy plus local treatment to the primary
tumor and metastases. This recommendation is based on two phase II studies showing that local treatment after systemic treatment improves PFS.

These guidelines also note that NSCLC patients who receive targeted therapy and develop progression can be treated with SBRT in order to continue receiving the targeted treatment. In patients with asymptomatic brain metastases susceptible to treatment with TKIs, the guidelines recommend starting with TKI therapy and postponing local treatment (surgery or radiosurgery).

**National Comprehensive Cancer Network**

The National Comprehensive Cancer Network guidelines include local treatment (SBRT or surgery) of metastases in well-selected patients with good ECOG performance status who have received radical treatment to the intrathoracic disease[101].

In patients with limited brain metastases, the guidelines recommend local treatment of these lesions (by surgery or radiosurgery). In patients with asymptomatic brain metastases with mutations, it is acceptable to continue with TKI, only administering local treatment if the lesions become symptomatic.

SBRT or surgery to the oligometastatic lesions (one to five metastases) is recommended provided that all sites can be safely treated. In patients who develop disease progression in a limited number of sites following systemic treatment, the use of SBRT may extend the duration of the benefit from that line of systemic treatment. These recommendations also apply to patients with driver mutations that progress to targeted therapy in some locations. In these cases, SBRT can be applied to allow the patient to continue with the same treatment. If SBRT is not feasible at the oligoprogression sites, the guidelines recommend using other hypofractionated treatments.

**European Society for Medical Oncology**

The European Society for Medical Oncology guidelines[99] recommend local treatment with SBRT or surgery in the following situations: (1) Patients with a limited number of brain metastases who fulfil criteria for class I-II recursive partitioning analysis (RPA). WBRT can be obviated if the patient is closely monitored using brain MRI after local treatment; (2) In patients with mutations (EGFR, ALK, etc) and asymptomatic brain metastases, TKI can be started and radiosurgery delayed; (3) Stage IV patients with extracranial oligometastases and one to three synchronous metastases. In this case, DFS may improve if systemic treatment is combined with local treatment (SBRT). The guidelines recommend presenting these cases to a multidisciplinary tumor board due to the current lack of evidence; (4) In patients with mutations who develop oligoprogression. SBRT or surgery should be considered to prolong DFS and to continue with systemic therapy; and (5) In single contralateral pulmonary lesions that would be considered as a second synchronous tumor and would be treated with curative intent if possible.

**FUTURE DIRECTIONS AND CLINICAL TRIALS CURRENTLY UNDERWAY**

Based on the current evidence, local treatment—either surgery or SBRT—of patients with oligometastatic NSCLC is associated with good survival rates with acceptable toxicity[33,34,102]. Numerous prospective studies are currently underway to corroborate these results. The following table summarizes the relevant trials that are currently registered in ClinicalTrials.gov (Table 3)[103].

**CONCLUSION**

Oligometastatic NSCLC is a heterogeneous disease. These patients may present brain and body metastases, which can be synchronous or metachronous. Most studies performed to date have limited the number of metastases to no more than five lesions, thus limiting our ability to extrapolate results from those studies to patients with more widely disseminated disease. Nevertheless, due to the technological advances and improvements in the therapeutic strategy in recent years, this an exciting time for specialists who manage oligometastatic NSCLC. In recent years, numerous studies, including two randomized phase II trials, have demonstrated that local treatment, either radiotherapy or surgery, of the primary tumor and metastases improves PFS and OS in patients who present with oligometastatic NSCLC at diagnosis and in those who respond to the initial systemic therapy.
### Table 3 Clinical trials in patients with oligometastatic non-small cell lung cancer

| Clinical trial identifier | Title                                                                 | Objective                                                                                                                                                                                                 |
|--------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| NCT01185639              | Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-Small Cell Lung Cancer | To evaluate the efficacy of SBRT in oligometastatic NSCLC patients who achieve partial response or stable disease after 4 cycles of ChT. The hypothesis is that SBRT after 4 cycles of ChT is feasible, safe, with good local control, and improves time to progression. |
| NCT 02314364             | A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC | To evaluate SBRT in patients with stage 4 NSCLC and EGFR, ALK, or ROS1 mutations who have been treated with erlotinib, gefitinib, or other targeted drugs.                                                          |
| NCT03275597              | Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-Small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition | To evaluate the safety and tolerability of SBRT combined with durvalumab and tremelimumab for oligometastatic NSCLC.                                                                                       |
| NCT02975609              | Phase II Trial of SBRT Compared With Conventional Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer | To compare the efficacy and safety of SBRT vs conventional radiotherapy after response to 4-6 cycles of chemotherapy. Outcome measures for both groups include PFS, OS, and adverse effects. |
| NCT03808337              | Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease | To determine if SBRT to all oligometastatic lesions can extend time to progression.                                                                                                                         |
| NCT02417662              | Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer (SARCON) | Phase III study of efficacy and safety in oligometastatic NSCLC patients comparing conventional ChT alone to ChT plus conventional radiotherapy to the primary tumor and SBRT to the metastases. |

SBRT: Stereotactic body radiation therapy; NSCLC: Non-small cell lung cancer; ChT: Chemotherapy; PFS: Progression-free survival; OS: Overall survival.

As we await the results of ongoing randomized phase III trials, the main international clinical guidelines recommend a multimodal strategy to manage this subgroup of oligometastatic patients. Current guidelines recommend systemic therapy combined with local treatment of the metastases and, if applicable, the primary tumor. However, the optimal therapeutic approach for the specific type of oligometastatic disease (intracranial vs extracranial, synchronous vs metachronous) remains to be defined. Given that no studies have been performed to compare radiotherapy to surgery in this setting, treatment selection (surgery vs radiotherapy, with or without systemic treatment) must be based on individualized prognostic factors, which allow us to classify patients in order to select the most appropriate therapeutic strategy for that particular patient. In the future, the availability of molecular or microRNA profiles is expected to improve patient selection.

### REFERENCES

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. *Eur J Cancer* 2013; 49: 1374-1403 [PMID: 23485231 DOI: 10.1016/j.ejca.2012.12.027]  
2. Juan O, Popat S. Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer. *Clin Lung Cancer* 2017; 18: 595-606 [PMID: 28377206 DOI: 10.1016/j.clic.2017.03.002]  
3. Eberhardt WE, Mitchell A, Crowley H, Kondo H, Kim YT, Turrisi A, Goldstraw P, Rami-Porta R; International Association for Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Board Members, and Participating Institutions. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. *J Thorac Oncol* 2015; 10: 1515-1522 [PMID: 26536193 DOI: 10.1097/JTO.0000000000000673]  
4. Hellman S, Weichselbaum RR. Oligometastases. *J Clin Oncol* 1995; 13: 8-10 [PMID: 7799047 DOI: 10.1200/JCO.1995.13.1.8]  
5. Bergsma DP, Salama JK, Singh DP, Chmura SJ, Milano MT. Radiotherapy for Oligometastatic Lung Cancer. *Front Oncol* 2017; 7: 210 [PMID: 28975081 DOI: 10.3389/fonc.2017.00210]  
6. Ashworth AB, Senan S, Palma DA, Riquet M, Ahn YC, Ricardi U, Congedo MT, Gomez DR, Wright KL, Mollon G, Milano MT, Sole CV, De Pas TM, Carter DL, Warner AJ, Rodrigues GB. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. *Clin Lung Cancer* 2014; 15: 346-355 [PMID: 24084942 DOI: 10.1016/j.clic.2014.04.003]  
7. Rusthoven KE, Kavanagh BD, Cardenes H, Nieder WV, Burri SH, Feigenberg SJ, Child MA, Pugh TJ, Franklin W, Kane M, Gaspar LE, Schefter TE. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. *J Clin Oncol* 2009; 27: 1572-1578 [PMID: 19255321 DOI: 10.1200/JCO.2008.19.6329]
Nihei Y, Hayakawa K. Oligometastases and oligo-recurrence: the new era of cancer therapy. *Jpn J Clin Oncol* 2010; 40: 107-111 [PMID: 20047860 DOI: 10.1093/jco/hyp167]

Tännöes S, Tännöes M, Kollmeier J, Bauer TT, Förster GJ, Kaiser D, Werneck KD, Pfannschmidt J. Impact of preoperative 18F-FDG PET/CT on survival of resected metastatic non-small cell lung cancer. *Lung Cancer* 2016; 93: 28-34 [PMID: 26898611 DOI: 10.1016/j.lungcan.2015.12.008]

Dinan MA, Curtis LH, Carpenter WR, Biddle AK, Abernethy AP, Patz EF, Schulman KA, Weinberger M. Stage migration, selection bias, and survival associated with the adoption of positron emission tomography among medicare beneficiaries with non-small-cell lung cancer, 1998-2003. *J Clin Oncol* 2012; 30: 2725-2730 [PMID: 22753917 DOI: 10.1200/JCO.2011.40.4392]

Ashworth A, Rodrigues G, Boldt G, Palma D. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature. *Lung Cancer* 2013; 82: 197-203 [PMID: 24051084 DOI: 10.1016/j.lungcan.2013.07.026]

Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, Markesbery WR, Foon KA, Young B. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. *JAMA* 1998; 280: 1485-1489 [PMID: 9809728 DOI: 10.1001/jama.197.11.1485]

De Ruyscher D, Wanders R, van Baardwijk A, Dingemans AM, Reymen B, Houben R, Bootsta M, Pitz C, van Eijden L, Geraedt W, Baumert BG, Lambin P. Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450). *J Thorac Oncol* 2012; 7: 1547-1555 [PMID: 22982655 DOI: 10.1097/JTO.0b013e3182e62a6e]

Tännöes M, Pfannschmidt J, Bauer T, Kollmeier J, Tännöes S, Kaiser D. Metastasectomy for synchronous solitary non-small cell lung cancer metastases. *Ann Thorac Surg* 2014; 98: 249-256 [PMID: 24820385 DOI: 10.1016/j.athoracsur.2014.03.028]

Johnson KK, Rosen JE, Salazar MC, Bofill DJ. Outcomes of a Highly Selective Surgical Approach to Oligometastatic Lung Cancer. *Ann Thorac Surg* 2016; 102: 1166-1171 [PMID: 27344278 DOI: 10.1016/j.athoracsur.2016.04.086]

Pfannschmidt J, Dienermann H. Surgical treatment of oligometastatic non-small cell lung cancer. *Lung Cancer* 2010; 69: 251-258 [PMID: 20573426 DOI: 10.1016/j.lungcan.2010.05.003]

Lewis SL, Porceddu S, Nakamura N, Palmada DA, Lo SS, Hoskin P, D'Angelo P, Aboshi C, Falzon M, Borg E, Marafioti T, Lawrence D, Hayward M, Kolvekar S, Panagioutopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Shah R, Joseph L, Quinn AM, Cushing PA, Naidu B, Middleton G, Langman G, Trottier S, Nicolous M, Remmen H, Kerr K, Chetty M, Gomemall L, Fennell DA, Nakas A, Rathinam S, Anand K, Khan S, Russell P, Ehiyi V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Komazweska M, Amtmann R, Davies H, Davies D, Taner S, Tailby IA, Lovell D, Bell H, Ngai Y, Shah JA, Herrero J, Sallazsi Z, Schwartz R, Wérandt S, Aoued Z, Saad A, Le Queue J, Van Loo P, Dive C, Hackshaw A, Swanton C, TRACERKeep Consortium. Tracking the Evolution of Non-Small-Cell Lung Cancer. *N Engl J Med* 2017; 376: 2109-2121 [PMID: 28445112 DOI: 10.1056/NEJMoa1616288]

Mehta N, Mauer AM, Hellman S, Haraf DJ, Cohen EE, Vokes EE, Weichselbaum RR. Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment. *J Natl Cancer Inst* 2004; 96: 1677-1683 [PMID: 15547705 DOI: 10.1093/jnci/djh351]

Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, Shafi S, Johnson DH, Mitter R, Rosenthal R, Sahn M, Horswell S, Escudero M, Matthews N, Rowan A, Chambers T, Moore DA, Turajlic S, Xu H, Lee SM, Forster MD, Ahmad T, Hiley CT, Abbasch C, Falzon M, Borg E, Marafioti T, Lawrence D, Hayward M, Kolvekar S, Panagioutopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Shah R, Joseph L, Quinn AM, Cushing PA, Naidu B, Middleton G, Langman G, Trottier S, Nicolous M, Remmen H, Kerr K, Chetty M, Gomemall L, Fennell DA, Nakas A, Rathinam S, Anand K, Khan S, Russell P, Ehiyi V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Komazweska M, Amtmann R, Davies H, Davies D, Taner S, Tailby IA, Lovell D, Bell H, Ngai Y, Shah JA, Herrero J, Sallazsi Z, Schwartz R, Wérandt S, Aoued Z, Saad A, Le Queue J, Van Loo P, Dive C, Hackshaw A, Swanton C, TRACERKeep Consortium. Tracking the Evolution of Non-Small-Cell Lung Cancer. *N Engl J Med* 2017; 376: 2109-2121 [PMID: 28445112 DOI: 10.1056/NEJMoa1616288]

Jones CM, Brunelli A, Callister ME, Franks KN. Multimodality Treatment of Advanced Non-small Cell Lung Cancer: Where are we with the Evidence? *Curr Surg Rep* 2018; 6: 5 [PMID: 29456881 DOI: 10.1007/s40137-018-0202-0]

Hasselle MD, Haraf DJ, Rushoveen KE, Golden DW, Salgia R, Villafior VM, Shah N, Hoffman PC, Chmura SJ, Connell PP, Vokes EE, Weichselbaum RR. Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. *J Thorac Oncol* 2012; 7: 376-381 [PMID: 22199429 DOI: 10.1097/JTO.0b013e31825e792a]

Lo Res Guerra JL, Gomez D, Zhaung Y, Hong DS, Heymach JV, Swisher SG, Lin SH, Komaki R, Cox JD, Liao Z. Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis. *Int J Radiat Oncol Biol Phys* 2012; 84: e61-e67 [PMID: 22503522 DOI: 10.1016/j.ijrobp.2012.02.054]

Mordant P, Arame A, De Dominicis F, Priscop C, Foucault C, Daionn A, Le Pimpec-Barthes F, Riquet M. Which metastasis management allows long-term survival of synchronous solitary Mib1 non-small cell lung cancer? *Eur J Cardiothorac Surg* 2012; 41: 617-622 [PMID: 22237300 DOI: 10.1093/ejcts/ezt042]

Khan AJ, Mehta PS, Zuzug TW, Bonomi PD, Penfield Faber L, Shott S, Abrams RA. Long term disease-free survival resulting from combined modality management of patients presenting with oligo-metastatic, non-small cell lung carcinoma (NSCLC). *Radiother Oncol* 2006; 81: 163-167 [PMID: 17050016 DOI: 10.1016/j.radonc.2006.09.006]

Grilloh GH, Toguri D, Dahele M, Warner A, de Haan PD, Rodrigues GB, Slotman BJ, Yaremko BG, Senan S, Palma DA. Radical treatment of synchronous oligometastatic non-small cell lung cancer (NSCLC): patient outcomes and prognostic factors. *Lung Cancer* 2013; 82: 95-102 [PMID: 23973202 DOI: 10.1016/j.lungcan.2013.07.023]

Cinco L, Taberna A, Chiapella F, Pescatore M, Amento M, Amento P, Amento P. Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer. *Int J Radiat Oncol Biol Phys* 2014; 89: 2109-2121 [PMID: 28445112 DOI: 10.1056/NEJMoa1616288]

Couñago F et al. Oligometastatic non-small cell lung cancer
body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer 2012; 118: 2962-2970 [PMID: 22020702 DOI: 10.1002/cncr.26611]

30 De Ryrssecher D, Wanders R, Hendriks LE, van Baardwijk A, Reymsen B, Houben R, Bootma G, Pitz C, van Eijden L, Dingemans AC. Progression-Free Survival and Overall Survival Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450). J Thorac Oncol 2018; 13: 1958-1961 [PMID: 30253974 DOI: 10.1016/j.jtho.2018.07.098]

31 Iyenagur P, Wardak Z, Gerber DE, Tumani V, Ahn C, Hughes RS, Dowell JE, Cheedella N, Nedzi L, Westover KD, Pulparracharuwil S, Choy H, Timmerman RD. Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol 2018; 4: e173501 [PMID: 28973074 DOI: 10.1001/jamaoncol.2017.3501]

32 Gomez DR, Blumenschein GR, Lee JI, Hernandez M, Ye R, Camidge DR, Doeeble RC, Skoulidis F, Gaspar LE, Gibbons DL, Karam JA, Kavanagh BD, Tang C, Komrak L, Louie AV, Palmia DA, Tsao AS, Sepesi B, William NW, Zhng J, Shi Q, Wang XS, Swisher SG, Heymach J. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol 2016; 17: 1672-1682 [PMID: 27789196 DOI: 10.1016/S1470-2045(16)30530-0]

33 Gomez DR, Tang C, Zhang J, Blumenschein GR, Hernandez M, Lee JI, Ye R, Camidge DR, Skoulidis F, Doeeble R, Gaspar LE, Gibbons DL, Karam J, Kavanagh BD, Palma DA, Louie AV, Tsao AS, Sepesi B, Swisher SG, Heymach J. Local Consolidative Therapy (LCT) Improves Overall Survival (OS) Compared to Maintenance Therapy/Observation in Oligometastatic Non-Small-Cell Lung Cancer (NSCLC): Final Results of a Multicenter, Randomized, Controlled Phase 2 Trial. Int J Radiat Oncol 2018; 102: 1604 [DOI: 10.1016/j.ijrobp.2018.08.070]

34 Palma DA, Olson RA, Harrow S, Gaede S, Louie AV, Haasbeek C, Mulroy LA, Lock MI, Rodrigues G, Yarenko BP, Schellenberg D, Ahmad B, Griffioen G, Senthi S, Liu MC, Moore K, Currie S, Baumann GS, Warner A, Senan S. Stereotactic Ablative Radiation Therapy for the Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET): Results of a Randomized Trial. Int J Radiat Oncol Biol Phys 2018; 102: S3-4 [DOI: 10.1016/j.ijrobp.2018.06.105]

35 Sutera P, Kalaris K, Clump DA, D’Ambrosio D, Mihai A, Burton SA, Heron DE. Stereotactic Ablative Radiation Therapy for Unresectable Colorrectal Oligometastases. Adv Radiat Oncol 2018; 4: 57-62 [PMID: 30796011 DOI: 10.1016/j.adro.2019.09.001]

36 Petty WJ, Urbanic JJ, Almein T, Hughes R, Levine B, Rusthoven K, Papapilos M, Ruiz JR, Lally BE, Chan M, Clark H, D’Agostino RB, Blackstock AW. Long-Term Outcomes of a Phase 2 Trial of Chemotherapy With Consolidative Radiation Therapy for Oligometastatic Non-Small Cell Lung Cancer. J Int Radiat Oncol Biol Phys 2018; 102: 527-533 [PMID: 30003996 DOI: 10.1016/j.ijrobp.2018.06.040]

37 Parikh RB, Cronin AM, Kozono DE, Oxandar GR, Mak RK, Jackson DM, Lo PC, Baldini EH, Johnson BE, Chen AB. Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer. J Radiat Oncol Biol Phys 2014; 89: 880-887 [PMID: 24867533 DOI: 10.1016/j.jrobp.2014.04.007]

38 Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991; 9: 1618-1626 [PMID: 1651932 DOI: 10.1200/JCO.1991.9.9.1618]

39 Dai C, Ren Y, Xie D, Zheng H, She Y, Fei K, Jiang G, Chen C. Does Lymph Node Metastasis Have a Negative Prognostic Impact in Patients with NSCLC and M1A Disease? J Thorac Oncol 2016; 11: 1745-1754 [PMID: 27567989 DOI: 10.1016/j.jtho.2016.06.030]

40 Milano MT, Vokes EE, West JH, Salama JK. Oligometastatic non-small cell lung cancer - UpToDate [Internet]. Available from: https://www.uptodate.com/contents/oligometastatic-non-small-cell-lung-cancer?search=oligometastatico&source=search_result&selectedTitle=1~69&usage_type=default&display_rank=1

41 Collaud S, Staelin R, inci HI, Hillinger S, Schneider D, Kestenholz P, Weder W. Survival of patients treated surgically for synchronous single organ metastatic NSCLC and advanced pathologic TN stage. Lung Cancer 2012; 78: 234-238 [PMID: 23040135 DOI: 10.1016/j.lungcan.2012.06.003]

42 Divisi A, Barone M, Zaccagna G, Gabriele F, Crisci R. Surgical approach in the oligometastatic patient. Ann Transl Med 2018; 6: 94 [PMID: 29666817 DOI: 10.21037/atm.2018.01.19]

43 Francesco D, De Rosse F, Franzo C, Comito T, Di Brina L, Radicioni G, Evangelista A, D’Agostino GR, Navarrina P, Scorsetti M. Predictive Factors for Response and Survival in a Cohort of Oligometastatic Patients Treated With Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys 2019; 104: 111-121 [PMID: 30630030 DOI: 10.1016/j.ijrobp.2018.12.049]

44 Frost N, Tessmer A, Schmittlet A, van Laak V, Raspe M, Rauewe-Glisenkamp C, Brunn M, Senger C, Böhmer D, Ochsenreither S, Temmesfeld-Wollbrück B, Schmidt B, Neudecker J, Rückert JC, Stock A, Züchner M, Gerhol C. Local ablative treatment for synchronous single organ oligometastatic lung cancer-A propensity score analysis of 180 patients. Lung Cancer 2018; 125: 164-173 [PMID: 30429016 DOI: 10.1016/j.lungcan.2018.09.021]

45 Li S, Zhu R, Li D, Li N, Zhu X. Prognostic factors of oligometastatic non-small cell lung cancer: a meta-analysis. J Thorac Dis 2018; 10: 3701-3713 [PMID: 30069358 DOI: 10.21037/jtd.2018.05.105]

46 Lussiez YA, Xing HR, Salama JK, Khour Y, Zhang Y, Balsetine MC, Tang TE, Malik F, Farah S, Filippo M, Corbin K, Lee Y, Posner MC, Chmura SJ, Hellman S, Weichselbaum RR. MicroRNA expression characterizes oligometastases(e). PLoS One 2011; 6: e28650 [PMID: 22174856 DOI: 10.1371/journal.pone.0028650]

47 Schouten LJ, Rutten HA, Twijnstra A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, lung and melanoma. Cancer 2002; 94: 2698-2705 [PMID: 12173339 DOI: 10.1002/cncr.10541]

48 Ostrom QT, Wright CH, Barnhooltz-Sloan JS. Brain metastases: epidemiology. Handb Clin Neurol 2018; 149: 27-42 [PMID: 29307358 DOI: 10.1016/B978-0-12-411161-1.00002-5]

49 Villaruz LC, Kobiic GJ, Socinski MA. Management of non-small-cell lung cancer with oligometastasis. Curr Oncol Rep 2012; 14: 333-341 [PMID: 22535905 DOI: 10.1007/s11912-012-0240-1]

50 Hu C, Chang EL, Hassenen SG, Allen PK, Woo SY, Mahajan A, Komaki R, Liao Z. Non-small cell lung cancer presenting with synchronous solitary brain metastasis. Cancer 2006; 106: 1998-2004 [PMID: 16572401 DOI: 10.1002/jca.21818]

51 Lamba N, Mueckens IS, DiRiso AC, Meijer L, Briceno V, Edrees H, Aslam B, Minhas S, Veenfoej JIC, Kleyven CE, Smith TR, Mckay RA, Broekman ML. Stereotactic radiurgery versus whole-brain
radiotherapy after intracranial metastasis resection: a systematic review and meta-analysis. *Radiat Oncol* 2017; 12: 106 [PMID: 2864695 DOI: 10.1186/s13014-017-0840-x]

52 Mahajan A, Ahmed S, McAleer MF, Weinberg JS, Li J, Brown P, Settle S, Prabhu SS, Lang FF, Levine N, McGovern S, Soliman E, McCutcheon IE, Azeem S, Callah D, Tatsui C, Heimberger AB, Ferguson S, Ghia A, Demonte F, Raza S, Guha-Thakurta N, Yang J, Sawaya R, Hess KR, Rao G. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. *Lancet Oncol* 2017; 18: 1040-1048 [PMID: 28687375 DOI: 10.1016/S1470-2045(17)30414-X]

53 Andrews DW, Scott CB, Spedero PW, Flanders AE, Gaspar LE, Schell MC, Werner-Wasik M, Demens W, Rya J, Bahary JP, Souliani M, Rotman M, Mehta MP, Curran WJ. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. *Lancet* 2004; 363: 1665-1672 [PMID: 15186267 DOI: 10.1016/S0140-6736(04)67250-8]

54 Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, Kenjo M, Oya N, Hirota S, Shiojura H, Kunieda E, Inomata T, Hayakawa K, Katoh N, Kobashi G. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. *JAMA* 2006; 295: 2483-2491 [PMID: 16757720 DOI: 10.1001/jama.295.21.2483]

55 Bhatnagar AK, Flickinger JC, Kondziolka D, Lunsford LD. Stereotactic radiosurgery for four or more intracranial metastases. *Int J Radiat Oncol Biol Phys* 2006; 64: 898-903 [PMID: 16338097 DOI: 10.1016/j.ijrobp.2005.08.015]

56 Tsao M, Xu W, Sahgal A. A meta-analysis evaluating stereotactic radiosurgery, whole-brain radiotherapy, or both for patients presenting with a limited number of brain metastases. *Cancer* 2012; 118: 2486-2493 [PMID: 22168763 DOI: 10.1002/cncr.26515]

57 Muacevic A, Wowa B, Sievert A, Tonn JC, Steiger HJ, Krest FH. Microsurgery plus whole brain irradiation versus Gamma Knife surgery alone for treatment of single metastases to the brain: a randomized controlled multicentre phase III trial. *J Neurooncol* 2008; 87: 299-307 [PMID: 18157648 DOI: 10.1007/s11060-007-9510-4]

58 Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Pérol M, Dzidzioienus R, Rosell R, Zeaiter A, Mitry I, Golding S, Balles B, Noe J, Morcos PN, Mok T; ALEX Trial Investigators. Alecetinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. *N Engl J Med* 2017; 377: 829-838 [PMID: 28595629 DOI: 10.1056/NEJMoa1607979]

59 Soria JC, Ohe Y, Vannesteke K, Reugwetwattana T, Chweskygulow B, Lee KH, Dechaphuchank, Anuama F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marroti M, Rukazkenov Y, Ramalingam SS; FLAURA Investigators. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. *N Engl J Med* 2018; 378: 113-125 [PMID: 29181159 DOI: 10.1056/NEJMoa1713137]

60 Soria JC, Tan DSW, Chiari R, Wu YL, Paz-Ares L, Wolf J, Gelet SL, Orlov S, Cortinovis D, Wu CJ, Hochmair M, Cortot AB, Tsai CM, Moro-Sibilot D, Campello RG, McCulloch T, Sen P, Dugan M, Pantano S, Brandle F, Massaccesi C, de Castro G. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. *Lancet* 2017; 389: 917-929 [PMID: 28126333 DOI: 10.1016/S0140-6736(17)30124-2]

61 Magauna WJ, Lester-Coll NJ, Wu AJ, Yang TJ, Lockey NA, Gao KE, Kamin A, Patil T, Kavanagh BD, Camidge DR, Braunstein SE, Boreta LC, Balasubramanian SK, Ahluwalia MS, Rana NG, Attia A, Gettinger SN, Contessa JN, Yu JB, Chiang VL. Management of brain Metastases in Tyrosine Kinase Inhibitor-Naive Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis. *J Clin Oncol* 2017; 35: 1070-1077 [PMID: 28113019 DOI: 10.1200/JCO.2016.69.7141]

62 Bazhenova L, Newton P, Mason J, Bethel K, Nieva J, Kuhn P. Adrenal metastases in lung cancer: clinical implications of a mathematical model. *J Thorac Oncol* 2014; 9: 442-444 [PMID: 24736064 DOI: 10.1097/JTO.0000000000001133]

63 Bradley CT, Strong VE. Surgical management of adrenal metastases. *J Surg Oncol* 2014; 100: 39-42 [PMID: 24338382 DOI: 10.1002/jso.23486]

64 Strong VE, D’Angelica M, Tang L, Prete F, Gönen M, D’Angelica M, Tang L, Prete F, Gönen M, Coit D, Touijer KA, Fong Y, Brennan MF. Surgical management of adrenal metastases. *J Surg Oncol* 2014; 100: 113-125 [PMID: 24338382 DOI: 10.1002/jso.23480]

65 Pichta K, Camiën N, Furqan M, Hejiej TA, Clamon GH, Zhang J, Flynn RT, Blatka S, Smith MC, Buatti JM, Allen BG. SBRT for adrenal metastases provides high local control with minimal toxicity. *Adv Radiat Oncol* 2017; 2: 581-587 [PMID: 29204525 DOI: 10.1016/j.adro.2017.07.011]

66 Scorsetti M, Alongi F, Filippini AR, Pavari A, Castiglioni S, Tozzi A, Reggiori G, Scirè G, Demonte F, Raza S, Guha-Thakurta N, Yang J, Chiu WH, Ryu J, Bahary JP, Souhami L, Roque M, Curran WJ. Whole brain radiation therapy with or without stereotactic radiosurgery boost for treatment of brain metastases: a randomised, open-label, phase 3 study. *Int J Radiat Oncol Biol Phys* 2012; 82: 919-923 [PMID: 21300473 DOI: 10.1016/j.ijrobp.2011.06.060]

67 Li J, Shi Z, Wang Z, Liu Z, Wu X, Shen Z, Li B, Song Y, Zhu X. Treating adrenal tumors in 26 patients with CyberKnife: a mono-institutional experience. *PloS One* 2013; 8: e60563 [PMID: 24278303 DOI: 10.1371/journal.pone.0060563]

68 Mahadevan A, Blanck O, Lanciano R, Peddada A, Sandararaman S, D’Ambrosio D, Sharma S, Perry D, Koller J, Davis J. Stereotactic Body Radiotherapy (SBRT) for liver metastasis - clinical outcomes from the international multi-institutional RSSEARCH® Patient Registry. *Radiat Oncol* 2018; 13: 26 [PMID: 29837070 DOI: 10.1186/s13014-018-0906-9]

69 Kennedy A. Radioembolization of hepatic tumors. *J Gastrointest Oncol* 2014; 5: 178-189 [PMID: 24982766 DOI: 10.3978/j.issn.2078-6891.2014.03.07]

70 Mahnkne AK, Pereira PL, de Baere T. Interventional oncologic approaches to liver metastases. *Radiology* 2013; 266: 407-430 [PMID: 23269294 DOI: 10.1148/radiol.12112544]

71 Rhim H, Goldberg SN, Dodd GD, Solbian L, Lim HK, Tonolino M, Cho OK. Essential techniques for successful radio-frequency thermal ablation of malignant hepatic tumors. *Radiographics* 2001; 21 Spec
Doebele RC, Camidge DR. Local ablative therapy of oligoprogressive disease prolongs disease control by

Weickhardt AJ, Dienstmann R, Riely GJ. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression

Ou SH, Jänne PA, Bartlett CH, Tang Y, Kim DW, Otterson GA, Crinò L, Selaru F, Cohen DP, Clark JW, Ronchi S, Orecchia R. Is Stereotactic Body Radiotherapy (SBRT) in lymph node oligometastases: quality of evidence and systematic review.

Jiang Y, Chen J, Wang L, Wang J, Jiang W, Yang D, Zhang Y, You Z, Li T, Gao X, Jin Q. Phase II study of stereotactic body radiotherapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer.

Dawson LA. Phase I study of individualized stereotactic body radiotherapy for malignant metastases.

Katz AW, Zhang H, Okumieff P. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study.

Bedard G, McDonald R, Poon I, Erler D, Soliman H, Cheung P, Chung H, Chu W, Loblaw A, Chow E, Sahgal A. Stereotactic body radiotherapy for non-spine bone metastases: quality of evidence and systematic review.

Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 1995; 60: 615-22; discussion 622-3

De Leyn P, Vroemen J, Vansteenkiste J, Verbeke E, Van Raemdonck D, Nafteux P, Decruyenaere J, Lerut T. Survival after resection of synchronous bilateral lung cancer. Eur J Cardiothorac Surg 2008; 34: 1215-1222

Rule W, Timmerman R, Tong L, Abdulrahman R, Meyer J, Boice T, Schwarz RE, Weatherall P, Chinsoo Cho L. Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases.

Pastorino U, Bayse M, Friedel G, Ginsberg RJ, Girard P, Goldstraw P, Johnston M, McCormack P, Pass H, Putnam JB, International Registry of Lung Metastases. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg 1997; 113: 37-49

Sahgal A. Stereotactic body radiation therapy for non-spine bone metastases--a review of the literature.

Sgourakis N, Vouyiouklis G, Katalagari I, Kostopoulos J, Konstantinou P, Valsamakis A, Gerunda G, Lumachi F. Image-guided robotic stereotactic radiosurgery for unresectable liver metastases: preliminary results. Anticancer Res 2009; 29: 3381-3384

Barrón ZL, Cardona AF, García O, Arén O, De la Garza J. Radical consolidative treatment provides a long-term survival benefit for patients with synchronous oligometastatic non-small cell lung cancer: A phase II study. Lung Cancer 2018; 126: 194-200

Rule W, Timmerman R, Tong L, Abdulrahman R, Meyer J, Boice T, Schwarz RE, Weatherall P, Chinsoo Cho L. Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases.

Ann Surg Oncol 2011; 18: 1083-1087

Scorsetti M, Arcangeli S, Tozzi A, Comtois T, Alongi F, Navarrìa P, Manconsì P, Reggiori G, Fogliata A, Torrìzzi G, Tomatis S, Cozzi L. Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a phase 2 trial. Int J Radiat Oncol Biol Phys 2013; 86: 336-342

Vollolìni L, Rapicetta C, Luzzi L, Ghiribelli C, Paladini P, Granato F, Gallazzi M, Gottì G. Surgical treatment of synchronous multiple lung cancers located in a different lobe or lung: high survival in node-negative subgroup. Eur J Cardiothorac Surg 2010; 37: 1198-1204

Nakamura H, Kauyuki S, Kawasada N, Taguchi M, Kato H. History of limited resection for non-small cell lung cancer. Ann Thorac Cardiovasc Surg 2005; 11: 356-362

Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 1995; 60: 615-22; discussion 622-3

De Leyn P, Moons J, Vansteenkiste J, Verbeke E, Van Raemdonck D, Nafteux P, Decruyenaere J, Lerut T. Survival after resection of synchronous bilateral lung cancer. Eur J Cardiothorac Surg 2008; 34: 1215-1222

Vollolìni L, Rapicetta C, Luzzi L, Ghiribelli C, Paladini P, Granato F, Gallazzi M, Gottì G. Surgical treatment of synchronous multiple lung cancers located in a different lobe or lung: high survival in node-negative subgroup. Eur J Cardiothorac Surg 2010; 37: 1198-1204

MT010-09-1125

MT010-09-1125

MT010-09-1125

MT010-09-1125

MT010-09-1125

MT010-09-1125
tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol 2012; 7: 1807-1814 [PMID: 23154552 DOI: 10.1097/JTO.0b013e3182745948]

98 Majem M, Juan O, Insa A, Reguart N, Trigo JM, Carcereny E, García-Campelo R, García Y, Guirado M, Provencio M. SIOM clinical guidelines for the treatment of non-small cell lung cancer (2018). Clin Transl Oncol 2019; 21: 3-17 [PMID: 30446985 DOI: 10.1007/s12094-018-1978-1]

99 Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD, Peters S. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019; 30: 863-870 [PMID: 30715166 DOI: 10.1093/annonc/mdy474]

100 Churilla TM, Weiss SE. Emerging Trends in the Management of Brain Metastases from Non-small Cell Lung Cancer. Curr Oncol Rep 2018; 20: 54 [PMID: 29736685 DOI: 10.1007/s11912-018-0695-9]

101 National Comprehensive Cancer Network Clinical Practice Guidelines. Non-Small Cell Lung Cancer (Version 3. 2019). Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf

102 Fleckenstein J, Petroff A, Schäfers HJ, Wehler T, Schöpe J, Rübe C. Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer. BMC Cancer 2016; 16: 348 [PMID: 27255302 DOI: 10.1186/s12885-016-2379-x]

103 ClinicalTrials.gov. [Accessed on 03.09.19]. Available from: https://clinicaltrials.gov

104 Collien C, Christian N, Schallier D, Meysman M, Duchateau M, Storme G, De Ridder M. Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic non-small-cell lung cancer patients. Ann Oncol 2014; 25: 1954-1959 [PMID: 25114022 DOI: 10.1093/annonc/mda370]
